Upstream Bio, Inc.
NASDAQ:UPB · NASDAQ Global Select
+$0.10 today
Vol 0.79M · Avg 0.66M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:UPB · Revenue to Net Income
Key Ratios
Analysis
$3.3M of revenue converted into -$156.8M of net income for the selected period. Gross margin is 98.8% and net margin is -4872.1%, showing how much revenue survives after costs and taxes. EPS is $-2.91, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.9M +20.4% | $2.4M -0.4% | $2.4M +96.4% | $1.2M | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $344.8M | $725.6M | $804.0M |
| Gross Profit | $2.9M +20.4% | $2.4M -0.4% | $2.4M +96.4% | $1.2M | $10.3B | $8.9B | $7.6B |
| Gross Margin | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 45.5% | 9.8% | 28.9% |
| Research & Development | $136.8M +117.3% | $63.0M +98.0% | $31.8M +70.4% | $18.7M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $26.4M +53.8% | $17.2M +60.5% | $10.7M +65.5% | $6.5M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $163.2M +103.7% | $80.1M +88.6% | $42.5M +69.2% | $25.1M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $188.0K +111.2% | $89.0K +48.3% | $60.0K +757.1% | $7.0K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$143.3M -128.4% | -$62.7M -206.3% | -$20.5M +14.2% | -$23.9M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | -5019.4% -2373.2pp | -2646.3% -1785.9pp | -860.4% +1108.4pp | -1968.7% | 10.0% | 5.6% | 46.3% |
| Operating Income | -$160.4M -106.2% | -$77.8M -93.9% | -$40.1M -67.8% | -$23.9M | $10.6B | $12.3B | $14.0B |
| Operating Margin | -5618.8% -2337.6pp | -3281.2% -1595.7pp | -1685.5% +287.2pp | -1972.7% | 18.7% | 16.6% | 24.1% |
| Interest Income | $16.9M +39.7% | $12.1M +191.1% | $4.2M +1931.7% | $205.0K | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $0 | $0 | $0 | $0 | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $16.9M +13.1% | $15.0M -23.6% | $19.6M +47648.8% | $41.0K | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$143.4M -128.4% | -$62.8M -205.8% | -$20.5M +14.0% | -$23.9M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | -5026.0% -2376.0pp | -2650.0% -1787.1pp | -862.9% +1106.4pp | -1969.3% | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $666.8M | $1.3B | -$1.6B |
| Net Income | -$143.4M -128.4% | -$62.8M -205.8% | -$20.5M +14.0% | -$23.9M | $5.0B | $4.9B | $4.8B |
| Net Margin | -5026.0% -2376.0pp | -2650.0% -1787.1pp | -862.9% +1106.4pp | -1969.3% | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$3 -78.5% | -$1 -41.9% | -$1 -59.1% | -$1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$3 -78.5% | -$1 -41.9% | -$1 -59.1% | -$1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $53.9M +4.9% | $51.3M +41.3% | $36.3M +0.0% | $36.3M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $53.9M +4.9% | $51.3M +41.3% | $36.3M +0.0% | $36.3M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.34B
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.78B
Pharvaris N.V.
NASDAQ:PHVS
$2.29B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.76B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.68B
Novavax, Inc.
NASDAQ:NVAX
$1.50B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.30B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.19B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.04M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does UPB generate?
Upstream Bio, Inc. (UPB) reported $2.85M of revenue in fiscal 2025.
Is UPB profitable?
Upstream Bio, Inc. (UPB) reported -$143,443,000.00 of net income, with a net margin of -5026.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.